Novel treatments for systemic amyloidosis
van Gameren II et al. – Article reviews the current treatments for systemic amyloidoses:- Current treatment is directed against an ongoing supply of precursor proteins
- Treatment modalities include:
- liver transplantation for transthyretin-related (ATTR) amyloidosis
- elimination of inflammation in amyloid A (AA) amyloidosis and
- intensive chemotherapy in immunoglobulin light chain (AL) amyloidosis
- These therapies often elicit substantial morbidity and mortality or insufficient effectiveness
- Therefore, the search for new, more effective therapies without serious side-effects remains mandatory
- Since cardiac involvement is vital when deciding on therapy, the introduction of N-terminal probrain natriuretic peptide (NT-proBNP) and troponin are of great importance
- New potent precursor-lowering drugs, such as thalidomide, lenalidomide and bortezomib, need to find their place in treatment protocols in AL amyloidosis [more...]
|
|
|
